LLY Eli Lilly and Company

Elanco Names Todd S. Young as New Chief Financial Officer

Regulatory News:

Elanco Animal Health Incorporated (NYSE:ELAN), today named Todd S. Young as executive vice president and chief financial officer (CFO), joining Elanco’s Executive Committee and reporting to Elanco president and chief executive officer, Jeffrey N. Simmons.

Young starts his new position at Elanco on November 1 at the company’s Greenfield, Indiana headquarters. Lucas Montarce, who has been serving as acting Elanco CFO, will return to Eli Lilly and Company as vice president and CFO of Lilly’s International Business Unit.

“I am pleased to welcome Todd to the Elanco Executive Team,” said Jeff Simmons, president and CEO of Elanco. “His deep financial expertise combined with his pharmaceutical industry knowledge make him an excellent addition to Elanco at this exciting time in our company’s history. We also thank Lucas Montarce for his dedication and commitment stepping in during a critical time.”

Young will have responsibility for Elanco’s financial operations. He has more than 20 years’ experience in a wide range of financial roles. Most recently, he was executive vice president and CFO for ACADIA Pharmaceuticals Inc. in San Diego. He also spent several years in varying financial leader roles at Baxter International and worked on the spin-off of Baxalta, which he then joined as senior vice president and treasurer. He started his career at law firm Sidley Austin L.L.P.

Over the past 20 years, Young has had experience in all sectors of corporate financial operations, including tax, treasury, mergers and acquisitions, and leading and building finance teams. He also spent time in international markets throughout his career.

About Elanco Animal Health

Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life – all to advance the health of animals, people and the planet. Learn more at .

EN
30/10/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eli Lilly and Company

Eli Lilly & Co: 1 director

A director at Eli Lilly & Co sold 750 shares at 753.600USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Pelham Smithers
  • Pelham Smithers

PSA Market Strategy: How Japan Transformed from a Bear Market to a Bul...

In our 2010 Japan Perspective, written close to the nadir of the bear market, we discussed what was wrong with Japan, but also what it was starting to do right. Fourteen years on, the Nikkei 225 - though not yet Topix - has hit a new all-time high. This report looks at how Japan built on those things that were going right, while also starting to address what else needed to be done, and looks at whether more is needed to be done if the market rally is to continue from here.

Moody's rates Eli Lilly's notes A1; stable outlook

Moody's Investors Service (Moody's) assigned an A1 rating to the new senior unsecured notes offering of Eli Lilly and Company ("Lilly"). There are no changes to Lilly's existing ratings including the A1 senior unsecured long-term rating and the Prime-1 short-term rating, or the stable outlook. RAT...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch